BioCardia Reports Second Quarter 2024 Business Highlights and Financial Results
- SUNNYVALE, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the second quarter of 2024 and filed its quarterly report on Form 10-Q for the three and six months ended June 30, 2024 with the Securities and Exchange Commission. The Company will also hold a conference call at 4:30 PM ET today in which it will discuss business highlights. Following management's formal remarks, there will be a question-and-answer session.
- 08/13/2024
|
Bet on 5 Top-Ranked Stocks With Rising P/E
- Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include TAL Education Group (TAL), BioCardia (BCDA), Angi (ANGI), Xcel Energy (XEL) and SoFi Technologies (SOFI).
- 08/12/2024
|
BioCardia Announces United States Patent Issuance on Morph DNA Multi-Directional Steerable Catheter Transseptal Application
- SUNNYVALE, Calif., July 17, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a company focused on cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases today announces that the Unites States Patent Office has granted Patent No: 12,036,371 titled “Method of Accessing the Left Atrium with a Multi-Directional Steerable Catheter,” with a patent term that will expire in 2035.
- 07/17/2024
|
BioCardia Announces United States Patent Issuance on Intramyocardial Delivery of Cell Aggregates to the Heart Including Minimally Invasive Radial Artery Approach
- BioCardia announces that the USPTO has granted Patent No: 11,986,611 titled “Radial and Transendocardial Delivery Catheter,” with a 2036 expiration date.
- 06/07/2024
|
BioCardia Announces Reverse Stock Split
- SUNNYVALE, Calif., May 21, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that, following approval by the Company's stockholders and its Board of Directors, the Company intends to effect a reverse stock split of its common stock at a ratio of 1 post-split share for every 15 pre-split shares. The reverse stock split will become effective at 12:01 a.m. Eastern Daylight Time on Thursday, May 30, 2024. The Company's common stock will begin trading on a split-adjusted basis when the market opens on Thursday, May 30, 2024. The Company's common stock and warrants will continue to be traded on The Nasdaq Capital Market under the ticker symbols “BCDA” and “BCDAW,” respectively. The reverse stock split is intended to increase the minimum bid price requirement for continued listing on The Nasdaq Capital Market. The Company, however, cannot assure that the price of its common stock after the reverse stock split will reflect the corresponding split ratio, that the price per share following the effective time will be maintained for any period of time, or that the price will remain above the pre-split trading price.
- 05/21/2024
|
BioCardia, Inc. (BCDA) Q1 2024 Earnings Call Transcript
- BioCardia, Inc. (NASDAQ:BCDA ) Q1 2024 Earnings Conference Call May 14, 2024 4:30 PM ET Company Participants Miranda Peto - IR Peter Altman - President and CEO David McClung - CFO Conference Call Participants Lander Egaña-Gorroño - H.C. Wainwright Operator Ladies and gentlemen, thank you for standing by.
- 05/14/2024
|
BioCardia Reports First Quarter 2024 Business Highlights and Financial Results
- SUNNYVALE, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the first quarter of 2024 and filed its quarterly report on Form 10-Q for the three months ended March 31, 2024 with the Securities and Exchange Commission. The Company will also hold a conference call at 4:30 PM ET today in which it will discuss business highlights. Following management's formal remarks, there will be a question-and-answer session.
- 05/14/2024
|
BioCardia to Host Q1 2024 Financial Results and Corporate Update Conference Call on May 14, 2024
- SUNNYVALE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will report its financial results for the the three months ended March 31, 2024 and provide a corporate update by conference call on Tuesday, May 14, 2024 at 4:30 PM ET. Following management's formal remarks, there will be a question-and-answer session.
- 05/09/2024
|
BioCardia's CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial Results Show Patient Benefits in Important Outcomes
- SUNNYVALE, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ: BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the primary endpoint results of the open label roll-in cohort of the CardiAMP® Cell Therapy in Chronic Myocardial Ischemia Trial.
- 05/01/2024
|
BioCardia Completes Enrollment of CardiAMP Cell Therapy for the Treatment of Chronic Myocardial Ischemia Trial Open Label Roll-In Cohort
- Call Scheduled for Study Clinical Leadership to Discuss Results and Details on Pivotal Randomized Trial Call Scheduled for Study Clinical Leadership to Discuss Results and Details on Pivotal Randomized Trial
- 04/25/2024
|
BioCardia, Inc. (BCDA) Q4 2023 Earnings Call Transcript
- BioCardia, Inc. (BCDA) Q4 2023 Earnings Call Transcript
- 03/27/2024
|
BioCardia Reports Fourth Quarter and Full Year 2023 Business Highlights and Financial Results
- SUNNYVALE, Calif., March 27, 2024 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the year ended December 31, 2023 and filed its annual report on Form 10-K with the Securities and Exchange Commission.
- 03/27/2024
|
BioCardia to Host 2023 Financial Results and Corporate Update Conference Call on March 27, 2024
- SUNNYVALE, Calif., March 20, 2024 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will report its financial results for the year ended December 31, 2023 and provide a corporate update by conference call on Wednesday, March 27, 2024 at 4:30 PM ET.
- 03/20/2024
|
BioCardia and StemCardia Announce Biotherapeutic Delivery Partnership
- BioCardia & StemCardia biotechnology company partnership targets heart failure, the leading cause of death and a condition with limited treatment options
- 03/13/2024
|
BioCardia Announces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study
- Centers for Medicare & Medicaid Services (CMS) approves reimbursement coverage of the confirmatory Phase III clinical trial of CardiAMP heart failure study
- 03/12/2024
|
BioCardia Reports Positive Interim Results from Phase III CardiAMP Cell Therapy Heart Failure Trial, with Compelling Data in Subgroup with Elevated NTproBNP Biomarker for Heart Failure
- SUNNYVALE, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. (Nasdaq: BCDA), a biotechnology company focused on advancing late-stage cell therapy interventions for cardiovascular disorders, today announced positive interim results from the Phase III randomized controlled trial of its CardiAMP® autologous cell therapy in 110 randomized patients with advanced chronic heart failure at a mean 20-month follow-up, (CardiAMP HF). Results showed reductions in heart death equivalents and MACCE, with a magnified reduction among patients with elevated NTproBNP, a common marker of heart distress. The data was presented today by Amish Raval, MD, Director of Clinical Cardiovascular Research and Professor of Medicine at the University of Wisconsin-Madison at the Technology and Heart Failure Therapeutics (THT) 2024 annual meeting.
- 03/04/2024
|
BioCardia Announces Activation of CardiAMP Heart Failure II Phase 3 Pivotal Study Recently Approved by FDA
- SUNNYVALE, Calif., Feb. 08, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. (“BioCardia” or the “Company”) (Nasdaq: BCDA), a biotechnology company focused on advancing late-stage cell therapy interventions for cardiovascular disorders, is targeting heart failure and chronic myocardial ischemia as potential indications for its biotherapeutic candidates: autologous CardiAMP® cell therapy and allogeneic CardiALLO™ cell therapy.
- 02/08/2024
|
BioCardia Announces Two Scientific Abstracts Have Been Accepted at the 2024 Technology and Heart Failure Therapeutics Conference
- SUNNYVALE, Calif., Jan. 31, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. (“BioCardia” or the “Company”) (Nasdaq: BCDA), a biotechnology company focused on advancing late-stage cell therapy interventions for cardiovascular disorders, is targeting heart failure and chronic myocardial ischemia as potential indications for its biotherapeutic candidates: autologous CardiAMP cell therapy and allogeneic CardiALLO cell therapy.
- 01/31/2024
|
BioCardia Biotherapeutic Delivery and Morph Access Innovations Business Development Update for Shareholders
- SUNNYVALE, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. (Nasdaq: BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, issues the following letter to shareholders:
- 01/03/2024
|
BioCardia Doses First Patient in CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells for the Treatment of Ischemic Heart Failure of Reduced Ejection Fraction
- SUNNYVALE, Calif., Dec. 19, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease, today announced that the first patient was enrolled and treated in its CardiALLO™ Allogeneic Mesenchymal Cell Therapy Phase I/II trial for the treatment of patients with New York Heart Association Class II and III ischemic heart failure of reduced ejection fraction (HFrEF).
- 12/19/2023
|
BioCardia Announces Expected CardiAMP Heart Failure Japan Approval Timeline Based on Pharmaceutical and Medical Device Agency Consultation Minutes
- SUNNYVALE, Calif., Dec. 18, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that Japan Pharmaceutical and Medical Device Agency (PMDA) minutes support the Company's understanding that CardiAMP autologous cell therapy may be approved for the treatment of patients with ischemic heart failure with reduced ejection fraction (HFrEF) based on follow-up data from the patients currently enrolled in the CardiAMP Heart Failure Trial (CardiAMP HF) that will be available in Q4 2024.
- 12/18/2023
|
BioCardia Shares Update from Japan PMDA Consultation on CardiAMP Autologous Cell Therapy for Ischemic Heart Failure; Foreign Data Expected to be Sufficient for Product Approval
- SUNNYVALE, Calif., Nov. 29, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today provided an update after its recent consultation with Japan's Pharmaceutical and Medical Device Agency (PMDA) towards approval of its CardiAMP autologous cell therapy for the treatment of patients with ischemic heart failure of reduced ejection fraction (HFrEF).
- 11/29/2023
|
BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules
- SUNNYVALE, Calif., Nov. 16, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA] (the “Company”), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor for the purchase and sale of 2,000,000 shares of the Company's common stock at a purchase price of $0.65 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules. The closing of the offering is expected to occur on or about November 20, 2023, subject to the satisfaction of customary closing conditions.
- 11/16/2023
|
BioCardia (BCDA) Soars 168% on FDA Nod to Heart Failure Study
- The FDA approves BioCardia's (BCDA) phase III study on its CardiAMP cell therapy to treat patients with ischemic heart failure.
- 11/15/2023
|
BioCardia Announces FDA Approval of CardiAMP Heart Failure II Protocol for Autologous Cell Therapy for Ischemic Heart Failure
- SUNNYVALE, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the Food and Drug Administration (FDA) approval of its Phase III clinical trial of its CardiAMP autologous cell therapy for the treatment of patients with ischemic heart failure.
- 11/14/2023
|
BioCardia, Inc. (BCDA) Q3 2023 Earnings Call Transcript
- BioCardia, Inc. (NASDAQ:BCDA ) Q3 2023 Earnings Conference Call November 8, 2023 4:30 PM ET Company Participants Miranda Peto - Investor Relations Peter Altman - President and Chief Executive Officer David McClung - Chief Financial Officer Operator Ladies and gentlemen, thank you for standing by and welcome to the BioCardia 2023 Third Quarter Conference Call. At this time, all participants are in a listen-only mode.
- 11/08/2023
|
BioCardia, Inc. (BCDA) Reports Q3 Loss, Tops Revenue Estimates
- BioCardia, Inc. (BCDA) came out with a quarterly loss of $0.12 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.17 per share a year ago.
- 11/08/2023
|
BioCardia to Host Q3 2023 Corporate Update and Financial Results Conference Call on November 8, 2023
- SUNNYVALE, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will provide a corporate update and report its financial results for the three and nine months ended September 30, 2023 by conference call on Wednesday, November 8, 2023 at 4:30 PM ET. Following management's formal remarks, there will be a question-and-answer session.
- 11/01/2023
|
BioCardia (BCDA) Up on Plans for Second Heart Failure Study
- BioCardia (BCDA) completes enrollment in a pivotal phase III study on its CardiAMP cell therapy for the treatment of heart failure. It plans to begin a second study with responders from the initial study.
- 10/12/2023
|
BioCardia (BCDA) Dips 26% on Flunking Heart Failure Study
- Based on one-year follow-up data from a pivotal phase III study, BioCardia (BCDA) reveals that its CardiAMP cell therapy is unlikely to achieve the primary endpoint for the treatment of heart failure.
- 09/06/2023
|
BioCardia shares slide on disappointing interim data from heart therapy trial
- BioCardia shares fell more than 20% in pre-market trade on Tuesday after the biopharmaceutical firm revealed that its Phase 3 trial of CardiAMP cell therapy for heart failure was unlikely to meet its three-tiered primary efficacy endpoint based on interim trial results. CardiAMP cell therapy uses a patient's own bone marrow cells delivered to the heart in a minimally invasive, catheter-based procedure to potentially stimulate the body's natural healing response.
- 09/05/2023
|
BioCardia, Inc. (BCDA) Reports Q2 Loss, Lags Revenue Estimates
- BioCardia, Inc. (BCDA) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.14 per share a year ago.
- 08/09/2023
|
BioCardia Announces Timing of the Next Data Safety Monitoring Board Meeting for the CardiAMP Cell Therapy in Heart Failure Pivotal Study
- SUNNYVALE, Calif., May 23, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases today announced that the next Data Safety Monitoring Board (DSMB) meeting for the CardiAMP Cell Therapy Trial for Heart Failure is scheduled to take place on July 12th. The Company expects the FDA's response to its adaptive statistical analysis plan supplement early to mid-June and anticipates approval of the plan and completion of all tasks to implement the plan, including all data monitoring, in advance of the DSMB meeting.
- 05/23/2023
|
BioCardia to Host Q1 2023 Financial Results and Corporate Update Conference Call on May 10, 2023
- SUNNYVALE, Calif., May 03, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will report its financial results for the three months ended March 31, 2023 and provide a corporate update by conference call on Wednesday, May 10, 2023 at 4:30 PM ET. Following management's formal remarks, there will be a question-and-answer session.
- 05/03/2023
|
BioCardia, Inc. (BCDA) Q4 2022 Earnings Call Transcript
- BioCardia, Inc. (NASDAQ:BCDA ) Q4 2022 Earnings Conference Call March 29, 2023 4:30 PM ET Company Participants Peter Altman - President & CEO David McClung - CFO Conference Call Participants Joe Pantginis - H.C. Wainwright Kumaraguru Raja - Roth Capital James Molloy - Alliance Global Partners Operator Ladies and gentlemen, thank you for standing by.
- 03/29/2023
|
BioCardia to Host 2022 Financial Results and Corporate Update Conference Call on March 29, 2023
- SUNNYVALE, Calif., March 16, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will report its financial results for the year ended December 31, 2022 and provide a corporate update conference call on Wednesday, March 29, 2023 at 4:30 PM ET. Following management's formal remarks, there will be a question-and-answer session.
- 03/16/2023
|
BioCardia, Inc. (BCDA) Q3 2022 Earnings Call Transcript
- BioCardia, Inc. (NASDAQ:BCDA ) Q3 2022 Earnings Conference Call November 9, 2022 4:30 PM ET Company Participants Jules Abraham - CORE IR Peter Altman - President & CEO David McClung - CFO Conference Call Participants Joe Pantginis - H.C. Wainwright Michael Okunewitch - Maxim James Molloy - Alliance Global Partners Operator Good day, and welcome to the BioCardia 2022 Third Quarter Conference Call.
- 11/12/2022
|
BioCardia, Inc. (BCDA) Reports Q3 Loss, Tops Revenue Estimates
- BioCardia, Inc. (BCDA) delivered earnings and revenue surprises of 26.09% and 6%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
- 11/09/2022
|
BioCardia, Inc. (BCDA) Upgraded to Buy: Here's What You Should Know
- BioCardia, Inc. (BCDA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- 11/09/2022
|
BioCardia to Host Q3 2022 Financial Results and Corporate Update Conference Call on November 9, 2022
- SUNNYVALE, Calif., Nov. 02, 2022 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will report its financial results for the three and nine months ended September 30, 2022 and provide a corporate update by conference call on Wednesday, November 9, 2022 at 4:30 PM ET. Following management's formal remarks, there will be a question-and-answer session.
- 11/02/2022
|
BioCardia Announces Participation at H.C. Wainwright Global Investment Conference September 12-14, 2022 (HYBRID CONFERENCE)
- SUNNYVALE, Calif., Sept. 09, 2022 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ, BCDA), today announced it will be featured as a presenting company at the H.C. Wainwright 24th Annual Global Investment Conference. The conference is being held on September 12-14, 2022. The in-person venue for the event is the Lotte New York Palace Hotel in New York City located at 455 Madison Avenue. Virtual participation will be staged simultaneously with over 500 company presentations scheduled as live feed or available on-demand.
- 09/09/2022
|
Has BioCardia (BCDA) Outpaced Other Medical Stocks This Year?
- Here is how BioCardia, Inc. (BCDA) and Ensign Group (ENSG) have performed compared to their sector so far this year.
- 08/24/2022
|
BioCardia, Inc. (BCDA) CEO Peter Altman on Q2 2022 Results - Earnings Call Transcript
- BioCardia, Inc. (NASDAQ:BCDA ) Q2 2022 Earnings Conference Call August 10, 2022 4:30 PM ET Company Participants Jules Abraham - IR, CORE IR Peter Altman - President and CEO David McClung - CFO Conference Call Participants Kumaraguru Raja - Brookline Capital Markets Michael Okunewitch - Maxim Group James Molloy - Alliance Global Partners Operator Ladies and gentlemen, thank you for standing by. Good day and welcome to the BioCardia 2022 Second Quarter Conference Call.
- 08/10/2022
|
BioCardia, Inc. (BCDA) Reports Q2 Loss, Tops Revenue Estimates
- BioCardia, Inc. (BCDA) delivered earnings and revenue surprises of 50% and 412.63%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
- 08/10/2022
|
BioCardia to Host Q2 2022 Financial Results and Corporate Update Conference Call on August 10, 2022
- SUNNYVALE, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will report its financial results for the three and six months ended June 30, 2022 and provide a corporate update by conference call on Wednesday, August 10, 2022 at 4:30 PM ET. Following management's formal remarks, there will be a question-and-answer session.
- 08/04/2022
|
BioCardia, Inc. (BCDA) Reports Q1 Loss, Lags Revenue Estimates
- BioCardia, Inc. (BCDA) delivered earnings and revenue surprises of -26.67% and 68.42%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
- 05/11/2022
|
BioCardia, Inc. (BCDA) CEO Peter Altman on Q1 2022 Results - Earnings Call Transcript
- BioCardia, Inc. (NASDAQ:BCDA ) Q1 2022 Earnings Conference Call May 11, 2022 4:30 PM ET Company Participants Jules Abraham - Investor Relations, CORE IR Peter Altman - President & Chief Executive Officer David McClung - Chief Financial Officer Conference Call Participants Kumaraguru Raja - Brookline Capital Markets Emanuela Branchetti - H.C. Wainwright Jim Molloy - Alliance Global Partners Operator Ladies and gentlemen, thank you for standing by.
- 05/11/2022
|
BioCardia (BCDA) Gains FDA Nod for ARDS Cell Therapy Study
- BioCardia (BCDA) gets FDA approval to start a phase I/II study to evaluate its allogenic stem cell therapy candidate, BCDA-04, in patients with ARDS due to COVID-19.
- 04/13/2022
|
FDA Approves BioCardia's Phase 1 Trial With Cell Therapy In COVID-19, Shares Jump
- The FDA has signed off BioCardia Inc's (NASDAQ: BCDA) Investigational New Drug (IND) application for BCDA-04 to initiate Phase 1/2 trial in adult patients recovering from Acute Respiratory Distress Syndrome (ARDS) due to COVID-19. BCDA-04 is a proprietary allogeneic mesenchymal.
- 04/12/2022
|
Top Penny Stocks to Buy? 3 As Stock Futures Climb Before Market Open
- Here's what you need to know about buying penny stocks on April 12th The post Top Penny Stocks to Buy? 3 As Stock Futures Climb Before Market Open appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 04/12/2022
|
BioCardia, Inc. (BCDA) CEO Peter Altman on Q4 2021 Results - Earnings Call Transcript
- BioCardia, Inc. (BCDA) CEO Peter Altman on Q4 2021 Results - Earnings Call Transcript
- 03/29/2022
|
BioCardia to Host 2021 Financial Results and Corporate Update Conference Call on March 29, 2022
- SUNNYVALE, Calif., March 24, 2022 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will report its financial results for the year ended December 31, 2021 and provide a corporate update conference call on Tuesday, March 29, 2022 at 4:30 PM ET. Following management's formal remarks, there will be a question and answer session.
- 03/24/2022
|
Safety Board Recommends BioCardia's Heart Failure Cell Therapy To Continue Unchanged
- The independent Data Safety Monitoring Board (DSMB) has completed its prespecified data review for BioCardia Inc's (NASDAQ: BCDA) ongoing Phase 3 CardiAMP Cell Therapy Heart Failure Trial. The DSMB based its review on all available data for the 108 patients enrolled with an additional six crossover patient procedures in the trial to date.
- 02/14/2022
|
Why Are BioCardia Shares Trading Higher Today?
- The FDA has granted Breakthrough Device Designation for BioCardia Inc's BCDA CardiAMP Cell Therapy System to treat heart failure. Get the Inside Access Traders Are Using to Profit More and Win Bigger.
- 02/03/2022
|
BioCardia To Release Third Quarter 2021 Financial Results November 10, 2021
- SAN CARLOS, Calif., Nov. 08, 2021 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a company focused on developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces it will release third quarter 2021 financial results on Wednesday, November 10, 2021 at 4:30PM ET.
- 11/08/2021
|
BCDA Stock: Why It Increased Today
- The stock price of BioCardia Inc (NASDAQ: BCDA) increased by over 4% today. This is why it happened.
- 10/12/2021
|
BioCardia Announces Participation at the A.G.P. Biotech & Specialty Pharma Conference October 13, 2021 (Virtual Conference)
- SAN CARLOS, Calif., Oct. 06, 2021 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (Nasdaq: BCDA), a company focused on developing cellular and cell derived therapeutics for the treatment of cardiovascular diseases, today announced it will be participating in the A.G.P Biotech & Specialty Pharma Conference taking place virtually on October 13, 2021.
- 10/06/2021
|
CardiAMP Cell Therapy Heart Failure Trial to be Featured in Two Presentations at Heart Failure Society of America Annual Meeting 2021
- SAN CARLOS, Calif., Sept. 10, 2021 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a company focused on developing cellular and cell derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces data from its CardiAMP® Cell Therapy Heart Failure pivotal trial (ClinicalTrials.gov Identifier: NCT02438306), which are being presented at the Heart Failure Society of America Annual Meeting 2021 on Saturday, September 11. This year's meeting provides a hybrid format; in-person at the Gaylord Rockies in Denver, Colorado or global live on-line access.
- 09/10/2021
|
BioCardia Announces Participation at the H.C. Wainwright 23rd Annual Global Investment Conference September 13-15, 2021 (Virtual Conference)
- SAN CARLOS, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (Nasdaq: BCDA), today announced it has recorded a company presentation that will be available on demand at the H.C. Wainwright 23rd Annual Global Investment Virtual Conference. The conference is being held as a virtual conference on September 13-15, 2021.
- 09/09/2021
|
BioCardia to Participate in Upcoming Investor Conferences
- SAN CARLOS, Calif., Aug. 13, 2021 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (Nasdaq: BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announced today that the Company's management team will participate in the following upcoming investor conferences:
- 08/13/2021
|
BioCardia Reports Second Quarter 2021 Financial Results and Business Highlights
- SAN CARLOS, Calif., Aug. 12, 2021 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the second quarter of 2021 and filed its quarterly report on Form 10-Q for the three and six months ended June 30, 2021 with the Securities and Exchange Commission.
- 08/12/2021
|
Will BioCardia, Inc. (BCDA) Report Negative Q2 Earnings? What You Should Know
- BioCardia, Inc. (BCDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 08/05/2021
|
BioCardia Announces Japanese Patent on Imaging System for Targeting Cardiac Therapies
- SAN CARLOS, Calif., July 15, 2021 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a company focused on cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases today announces that the Japan Patent Office has granted Patent No: 6887216 titled, “Target Site Selection, Entry, and Update With Automatic Remote Image Annotation” with a patent term that will expire on January 8, 2034.
- 07/15/2021
|
Why I've Taken A Small Position In BioCardia
- BCDA has candidate therapies that could potentially be curative of very prevalent heart diseases. The therapies have advanced to Phase 3 trials.
- 06/14/2021
|
BioCardia, Inc. (BCDA) Reports Q1 Loss, Tops Revenue Estimates
- BioCardia, Inc. (BCDA) delivered earnings and revenue surprises of 14.29% and 31.43%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
- 05/13/2021
|
BioCardia, Inc. (BCDA) Reports Q4 Loss, Misses Revenue Estimates
- BioCardia, Inc. (BCDA) delivered earnings and revenue surprises of 48.39% and -58.18%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
- 03/30/2021
|
BioCardia Is Super Cheap With Multiple Shots On Goal
- BioCardia has a leading-edge cardiac cell therapy platform. The company recently announced a settlement Term Sheet with Boston Scientific, BSX.
- 03/25/2021
|
BioCardia Announces Clinical Leadership Changes
- SAN CARLOS, Calif., Feb. 17, 2021 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA] a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced clinical leadership changes.
- 02/17/2021
|
Longeveron Seeks $25 Million IPO For Anti-Aging Efforts
- Longeveron Seeks $25 Million IPO For Anti-Aging Efforts
- 02/05/2021
|
BioCardia Update on Cell Therapy Product Development and 2021 Milestones
- SAN CARLOS, Calif., Feb. 02, 2021 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA] a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today provides an update on its cell therapy product development and 2021 milestones.
- 02/02/2021
|
Accomplished Biotech Executive Krisztina Zsebo, Ph.D. Joins BioCardia's Board of Directors
- SAN CARLOS, Calif., Jan. 11, 2021 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA] a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, welcomes Krisztina Zsebo, Ph.D., a 31-year veteran of the biotech industry, to its Board of Directors following her election at BioCardia's 2020 Annual Meeting of Stockholders in December 2020.
- 01/11/2021
|
Why These Health Care Stocks Are Moving Today
- Altimmune (NASDAQ: ALT) shares were trading higher Wednesday after the company announced it began a multinational Phase 2 clinical trial of HepTcellTM for the treatment of chronic Hepatitis B. Altimmune is a U.S.-based, clinical-stage immunotherapeutic biotechnology company.
- 12/30/2020
|
BioCardia Issued New U.S. Patent for Technology that Enhances Control for Cardiac Therapies
- Technology Anticipated to Impact Cardiac Biologic Therapies, Cardiac Arrhythmia, and Structural Heart Procedures Technology Anticipated to Impact Cardiac Biologic Therapies, Cardiac Arrhythmia, and Structural Heart Procedures
- 12/30/2020
|
BioCardia's stock pulls back after taking advantage of recent doubling with another share sale
- Shares of BioCardia Inc. sank 13.9% in morning trading Wednesday, after the developer of regenerative biologic therapies announced more stock sales in the wake of the 137.6% rocket ride over the past two days. The company said before Wednesday's open that it sold 2.04 million shares of its stock at $5.15 a share in a registered direct offering to raise $10.5 million, On Monday, the company said it sold 1.79 million shares at $4.75 a share in a registered direct offering to raise $8.5 million.
- 12/16/2020
|
BioCardia, Inc. Announces $10.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
- SAN CARLOS, Calif., Dec. 16, 2020 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (Nasdaq: BCDA) (BioCardia or the “Company”) today announced it has entered into definitive agreements with investors for the purchase and sale of 2,038,836 shares of its common stock at a purchase price of $5.15 per share in a registered direct offering priced at-the-market under Nasdaq rules. The closing of the offering is expected to occur on or about December 18, 2020, subject to the satisfaction of customary closing conditions.
- 12/16/2020
|
BioCardia, Inc. Announces $8.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules [Revised]
- SAN CARLOS, Calif., Dec. 15, 2020 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (Nasdaq: BCDA)(BioCardia or the “Company”) today announced it has entered into definitive agreements with investors for the purchase and sale of 1,789,474 shares of its common stock at a purchase price of $4.75 per share in a registered direct offering priced at-the-market under Nasdaq rules. The closing of the offering is expected to occur on or about December 16, 2020, subject to the satisfaction of customary closing conditions.
- 12/15/2020
|
BioCardia, Inc. Announces $8.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
- SAN CARLOS, Calif., Dec. 14, 2020 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (Nasdaq: BCDA)(BioCardia or the “Company”) today announced it has entered into definitive agreements with investors for the purchase and sale of 1,888,889 shares of its common stock at a purchase price of $4.75 per share in a registered direct offering priced at-the-market under Nasdaq rules. The closing of the offering is expected to occur on or about December 16, 2020, subject to the satisfaction of customary closing conditions.
- 12/14/2020
|
BioCardia News: Why BCDA Stock Is Soaring Today
- BioCardia (BCDA) news for Monday includes an announcement concerning interim clinical trial results boosting BCDA stock higher. The post BioCardia News: Why BCDA Stock Is Soaring Today appeared first on InvestorPlace.
- 12/14/2020
|
Why BioCardia, Pacific Biosciences And HCA Are Trading Higher Today
- BioCardia (NASDAQ: BCDA) shares are trading higher. The company said it anticipates data safety monitoring board verbal feedback by the end of Dec. 15 for its pivotal Phase 3 CardiAMP Heart Failure Trial.
- 12/14/2020
|
BioCardia Reports Published Study Showing Helix Biotherapeutic Delivery System Used in CardiAMP Phase III Heart Failure Trial Has Fewest Adverse Events Among Competitive Delivery Systems
- SAN CARLOS, Calif., Dec. 01, 2020 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA] today announced that the Company's proprietary Helix Biotherapeutic Delivery System (the Helix System) demonstrated the best safety profile among clinical transendocardial catheter injection systems used for cardiac cell therapy delivery in an in-press corrected proof published in the journal, Cardiovascular Revascularization Medicine. The Helix System is being used in the pivotal Phase III CardiAMP Heart Failure Trial currently enrolling nationwide for infusion of BioCardia's CardiAMP cell therapy to the myocardium.
- 12/01/2020
|
BioCardia Reports Third Quarter 2020 Financial Results and Business Highlights
- SAN CARLOS, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ: BCDA], a leader in the development of autologous and allogenic cell therapies, today reported financial results and business highlights for the third quarter of 2020 and filed its quarterly report on Form 10-Q for the three and nine months ended September 30, 2020 with the Securities and Exchange Commission on November 10, 2020.
- 11/10/2020
|
12 Healthcare Stocks Moving In Thursday's After-Market Session
- Gainers
Cassava Sciences (NASDAQ:SAVA) stock rose 20.61% to $10.65 during Thursday's after-market session. Today's trading volume for this security ended up closing at 271...
- 10/22/2020
|
BioCardia (NASDAQ:BCDA) Coverage Initiated by Analysts at Alliance Global Partners
- Alliance Global Partners initiated coverage on shares of BioCardia (NASDAQ:BCDA) in a report released on Monday morning, Stock Target Advisor reports. The brokerage issued a buy rating and a $11.50 price target on the stock. BCDA stock opened at $2.61 on Monday. BioCardia has a 52-week low of $2.01 and a 52-week high of $6.75. […]
- 09/22/2020
|
BioCardia Reports Second Quarter 2020 Financial Results and Business Highlights
- SAN CARLOS, Calif., Aug. 13, 2020 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today reported financial results and business highlights for the second quarter of 2020 and filed its quarterly report on Form 10-Q for the three and six months ended June 30, 2020 with the Securities and Exchange Commission on August 13, 2020. The Company is advancing its autologous and allogenic bone marrow-derived cell therapies for three cardiovascular indications and one respiratory indication.Second Quarter 2020 Business Highlights:Autologous Cell Therapies * The CardiAMP® Heart Failure program (BCDA-01) began the quarter with a positive recommendation from the independent data safety monitoring board to continue enrollment and ended the quarter resuming treatment of patients at centers that had paused elective procedures due to COVID-19. As of this date, 77 patients have been randomized. As a result of the current pandemic, the Company has taken steps to implement FDA guidance for clinical trials, including addressing unavoidable protocol deviations and implementing additional control measures. Clinical sites remain engaged and are resuming elective enrollment activities. * The CardiAMP Chronic Myocardial Ischemia program (BCDA-02), a pivotal trial for a second indication for CardiAMP cell therapy was activated. The University of Florida is the first study center and has completed its site initiation visit.Allogenic Cell Therapies * The Company’s response to the FDA’s comments on its Investigational New Drug Application for the CardiALLO™ Neurokinin-1 Receptor Positive Mesenchymal Stem Cell Program (BCDA-03) was completed and submitted to the Agency. The program is targeted to treat patients with heart failure who are ineligible for CardiAMP. * Pre-clinical work to pursue a program with these cells to treat acute respiratory distress developing from COVID-19 (BCDA-04) was also initiated.Corporate Developments * BioCardia was awarded a U.S. patent covering the Helix™ Biotherapeutic Delivery System, providing additional broad protection for the Helix system. * The Company closed a public offering of its common stock for gross proceeds of $11.5 million, including the exercise of the underwriter’s overallotment option. * The Company entered into a Litigation Funding Agreement, for the purpose of funding the legal proceedings relating to the case captioned Boston Scientific Corp., et al., v. BioCardia Inc. The legal proceedings are related to patents, patent applications, and trade secrets, which BioCardia asserts were misappropriated, and the proceeds from the sale of nVision to Boston Scientific in a $275 million deal.“Despite the COVID-19 challenges in the second quarter, we made progress in all four of our cell-based biotherapeutic development programs, as well as in manufacturing for our enabling device products, while also securing the financing and litigation support to continue our efforts in the year ahead,” said BioCardia Chief Executive Officer Peter Altman, PhD. “We are excited about the growing momentum in our cardiovascular cell programs, as well as the pre-clinical exploration of our cell therapy as a potential treatment for COVID-19 induced respiratory distress. We believe our unique approach using cells to enhance the body’s natural healing capabilities, rather than transform into new cells, has tremendous promise to help patients suffering from severe heart and respiratory disease.”Second Quarter 2020 Financial Results: * Net loss was $3.6 million for the second quarter of 2020, compared to $3.8 million in the second quarter of 2019. * Research and development expenses were $2.2 million in the second quarter of 2020, compared to $2.2 million in the second quarter of 2019, primarily reflecting expenses incurred while conducting the pivotal CardiAMP Heart Failure Trial and pivotal CardiAMP Chronic Myocardial Ischemia Trial, and further developing the Neurokinin-1 Receptor Positive Mesenchymal Stem Cell Program. * Selling, general and administrative expenses for the second quarter of 2020 totaled $1.4 million, compared to $1.4 million in the second quarter of 2019. * Net cash used in operations in the second quarter of 2020 was $2.3 million, compared to $2.3 million in the second quarter of 2019.Anticipated Upcoming Milestones: * Q3 2020: First patient treated in CardiAMP Chronic Myocardial Ischemia (CMI) Trial (BCDA-02) * Q3 2020: FDA acceptance of Investigational New Drug application for CardiALLO Neurokinin-1 Receptor Positive Mesenchymal Stem Cell Therapy (BCDA-03), the Company’s allogenic therapeutic platform, for the treatment of ischemic heart failure * Q4 2020: Pre-specified Data Safety Monitoring Board Review of all patients enrolled in the CardiAMP Heart Failure Trial, including futility analysis, based on sixty (60) patients that will have reached the primary one-year follow-up endpoint at the time of analysis (BCDA-01) * Q4 2020: Pre-specified Data Safety Monitoring Board Review of safety data from roll-in cohort in CardiAMP CMI Trial (BCDA-02) * Q4 2020: FDA acceptance of Investigational New Drug application for Neurokinin-1 Receptor Positive Mesenchymal Stem Cell Therapy (BDCA-04) for the treatment of Acute Respiratory Distress Syndrome as a result of COVID-19 * Q4 2020: Targeted commercial availability of Avance Transseptal SheathConference Call:BioCardia’s management will host a mid-year conference call for the investment community later today, August 13, 2020, at 8:30 AM ET to provide a corporate update and discuss these results. Following management’s formal remarks there will be a question and answer session.To listen to the call by phone, interested parties within the U.S. should call 1-877-270-2148 and international callers should call 1-412-902-6510. All callers should dial in approximately 10 minutes prior to the scheduled start time and ask to be joined into the BioCardia call. The conference call will also be available through a live webcast, which can be accessed through the following link: https://services.choruscall.com/links/bcda200813.html, which is also available through the company’s website at http://www.biocardia.com/investors/investor-information/id/1041.A webcast replay of the call will be available approximately one hour after the end of the call through November 13, 2020 at the above links. A telephonic replay of the call will be available through September 3, 2020 and may be accessed by calling 1-877-344-7529 (domestic) or 1-412-317-0088 (international) and using access code 10147151.About BioCardia BioCardia, Inc., headquartered in San Carlos, California, is developing regenerative biologic therapies to treat cardiovascular disease. CardiAMP autologous and Neurokinin-1 Receptor Positive allogenic cell therapies are the Company’s biotherapeutic platforms in clinical development. The Company's products include the Helix Biotherapeutic Delivery System and its steerable guide and sheath catheter portfolio. BioCardia also partners with other biotherapeutic companies to provide its Helix system and clinical support for their programs studying therapies for the treatment of heart failure, chronic myocardial ischemia and acute myocardial infarction. For more information, visit www.BioCardia.com.Forward Looking Statements This press release contains forward-looking statements that are subject to many risks and uncertainties. Forward-looking statements include, among other things, references to the enrollment of our clinical trials, the availability of data from our clinical trials, filings with the FDA, FDA product clearances, the efficacy and safety of our products and therapies, anticipated milestones, and other statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations. Such risks and uncertainties include, among others, the inherent uncertainties associated with developing new products or technologies, regulatory approvals, unexpected expenditures, the ability to raise the additional funding needed to continue to pursue BioCardia’s business and product development plans and overall market conditions. We may find it difficult to enroll patients in our clinical trials due to many factors, some of which are outside of our control. Slower than targeted enrollment could delay completion of our clinical trials and delay or prevent development of our therapeutic candidates. These forward-looking statements are made as of the date of this press release, and BioCardia assumes no obligation to update the forward-looking statements.We may use terms such as “believes,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” “approximately” or other words that convey the uncertainty of future events or outcomes to identify these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained herein, we caution you that forward-looking statements are not guarantees of future performance and that our actual results may differ materially from the forward-looking statements contained in this press release. As a result of these factors, we cannot assure you that the forward-looking statements in this press release will prove to be accurate. Additional factors that could materially affect actual results can be found in our documents filed with the SEC, including our recent filings on Form 8-K, Form 10-K and Form 10-Q, particularly any statements under the caption entitled “Risk Factors” Therein. BioCardia expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.Media Contact: Michelle McAdam, Chronic Communications, Inc. michelle@chronic-comm.
- 08/13/2020
|
BioCardia, Inc. (BCDA) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
- BioCardia, Inc. (BCDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 08/12/2020
|
BioCardia To Conduct Mid-Year Conference Call and Corporate Update August 13, 2020
- SAN CARLOS, Calif., Aug. 07, 2020 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced it will be conducting a mid-year corporate update conference call on Thursday, August 13, 2020 at 8:30AM ET. Following management’s formal remarks, there will be a question and answer session. To listen to the call by phone, interested parties within the U.S. should call 1-877-270-2148 and international callers should call 1-412-902-6510. All callers should dial in approximately 10 minutes prior to the scheduled start time and ask to be joined into the BioCardia call. The conference call will also be available through a live webcast, which can be accessed through the following link: https://services.choruscall.com/links/bcda200813.html, which is also available through the company’s website at http://www.biocardia.com/investors/investor-information/id/1041.A webcast replay of the call will be available approximately one hour after the end of the call through November 13, 2020 at the above links. A telephonic replay of the call will be available through September 3, 2020 and may be accessed by calling 1-877-344-7529 (domestic) or 1-412-317-0088 (international) and using access code 10147151. About BioCardia®: BioCardia, Inc., headquartered in San Carlos, Calif., is developing regenerative biologic therapies to treat cardiovascular disease. CardiAMP® autologous and NK1R+ allogenic cell therapies are the Company’s biotherapeutic platforms in clinical development. The Company's products include the Helix™ biotherapeutic delivery system and its steerable guide and sheath catheter portfolio. BioCardia also partners with other biotherapeutic companies to provide its Helix system and clinical support to their programs studying therapies for the treatment of heart failure, chronic myocardial ischemia and acute myocardial infarction. For more information, visit www.BioCardia.com.Forward Looking Statements: This press release contains forward-looking statements that are subject to many risks and uncertainties. Forward-looking statements include references to future enrollment in this second pivotal clinical trial and statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations. Such factors include, among others, the inherent uncertainties associated with developing new products or technologies and obtaining regulatory approvals. These forward-looking statements are made as of the date of this press release, and BioCardia assumes no obligation to update the forward-looking statements.INVESTOR CONTACT: David McClung, Chief Financial Officer investors@BioCardia.com, (650) 226-0120MEDIA CONTACT: Michelle McAdam, Chronic Communications, Inc. michelle@chronic-comm.com, (310) 902-1274
- 08/07/2020
|
LD Micro - Announces Preliminary List of Presenters for the LD-500.
- LOS ANGELES, CA / ACCESSWIRE / August 5, 2020 / LD Micro today announced the initial list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online.
- 08/05/2020
|
Innate Pharma (OTCMKTS:IPHYF) & BioCardia (OTCMKTS:BCDA) Financial Contrast
- Innate Pharma (OTCMKTS:IPHYF) and BioCardia (OTCMKTS:BCDA) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, risk, profitability, earnings and institutional ownership. Analyst Recommendations This is a breakdown of recent ratings and target prices for Innate Pharma and […]
- 08/04/2020
|
How Much Is BioCardia, Inc. (NASDAQ:BCDA) Paying Its CEO?
- Peter Altman became the CEO of BioCardia, Inc. (NASDAQ:BCDA) in 2002, and we think it's a good time to look at the...
- 07/22/2020
|
I-Mab (NASDAQ:BDTX) and BioCardia (NASDAQ:BCDA) Financial Survey
- I-Mab (NASDAQ:BDTX) and BioCardia (OTCMKTS:BCDA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, dividends, profitability, earnings, risk, analyst recommendations and institutional ownership. Analyst Ratings This is a breakdown of recent ratings and recommmendations for I-Mab and BioCardia, as provided […]
- 07/07/2020
|
BioCardia Announces Activation of Pivotal Trial Studying CardiAMP Cell Therapy Trial to Treat Chronic Myocardial Ischemia
- The purpose of the study is to determine the safety and efficacy of CardiAMP cell therapy in the treatment of patients with refractory angina pectoris and CMI. The FDA has said that the trial qualifies as a pivotal trial to produce the primary data to support market registration for the CardiAMP cell therapy for this significant unmet clinical need.
- 07/01/2020
|
BioCardia Announces CardiAMP Heart Failure Pivotal Trial Continues with First Patient Randomized in COVID-19 Era
- SAN CARLOS, Calif., July 01, 2020 -- BioCardia®, Inc., (OTC: BCDA), a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today.
- 07/01/2020
|
BioCardia Announces CardiAMP Heart Failure Pivotal Trial Continues with First Patient Randomized in COVID-19 Era
- BioCardia®, Inc., (BCDA), a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced that the Company has resumed cases in the CardiAMP Heart Failure Trial. The first patient procedure completed since elective procedures were paused due to COVID-19 took place at Morton Plant Hospital in Clearwater, Florida this month. “We are pleased to be able to resume enrollment at several sites for our lead clinical program and look forward to cases taking place in July and August,” said BioCardia CEO Peter Altman, PhD.
- 06/29/2020
|
Reviewing Rubius Therapeutics (NASDAQ:RUBY) & BioCardia (NASDAQ:BCDA)
- Rubius Therapeutics (NASDAQ:RUBY) and BioCardia (OTCMKTS:BCDA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, valuation, analyst recommendations, dividends and profitability. Earnings & Valuation This table compares Rubius Therapeutics and BioCardia’s revenue, earnings per share and valuation. […]
- 06/28/2020
|
BioCardia (OTCMKTS:BCDA) Shares Gap Down to $2.12
- BioCardia Inc (OTCMKTS:BCDA) gapped down prior to trading on Thursday . The stock had previously closed at $2.20, but opened at $2.12. BioCardia shares last traded at $2.22, with a volume of 501,462 shares changing hands. Separately, Maxim Group began coverage on BioCardia in a research report on Friday, May 1st. They issued a “buy” […]
- 06/20/2020
|
BIOCARDIA, INC. : Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits (form 8-K) | MarketScreener
|
The Daily Biotech Pulse: Eloxx Resumes Cystic Fibrosis Study, Rexahn's Reverse Merger, Ultragenyx, Epizyme Await FDA Decisions
- Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 17)
Adverum Biotechnologies Inc...
- 06/18/2020
|
BioCardia Announces Pricing of $10 Million Public Offering
- BioCardia®, Inc. NasdaqCM: BCDA (the “Company”), a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced the pricing of its public offering of 4,762,000 shares of common stock at a price to the public of $2.10 per share. BioCardia expects to receive gross proceeds of $10 million, before deducting underwriting discounts and commissions and other estimated offering expenses. BioCardia has granted the underwriters a 45-day option to purchase up to 714,190 additional shares of common stock, at the public offering price to cover over-allotments, if any.
- 06/17/2020
|
Zweites Gentherapieprodukt von Vivet, VTX-803 für PFIC3, in den USA und der EU als Arzneimittel für seltene Leiden (Orphan Drug) anerkannt
- Vivet Therapeutics meldete heute, dass sowohl die US-Food and Drug Administration (FDA) als auch die Europäische Kommission (EC) VTX-803, das zweite G
- 06/01/2020
|
BioCardia Reports First Quarter 2020 Financial Results and Business Highlights
- SAN CARLOS, Calif., May 15, 2020 -- BioCardia®, Inc. , a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today.
- 05/15/2020
|
Gene-Therapy Treatments for Tay-Sachs, Sickle Cell, Other Diseases to Be Featured in Online Gathering
- This week’s online annual meeting of the American Society for Gene and Cell Therapy will take place on the web.
- 05/12/2020
|
BioCardia Announces Positive Preclinical Results Supporting Investigational New Drug Application for Anti-Inflammatory Cell Therapy in Heart Failure
- SAN CARLOS, Calif., May 05, 2020 -- BioCardia®, Inc. , a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today.
- 05/05/2020
|
BioCardia (BCDA) Gets a Buy Rating from Maxim Group
- In a report released today, Jason McCarthy from Maxim Group assigned a Buy rating to BioCardia (BCDA), with a price target of $9.00. The company's shares
- 05/01/2020
|
BioCardia (BCDA) Gets a Buy Rating from Maxim Group
- In a report released today, Jason McCarthy from Maxim Group assigned a Buy rating to BioCardia (BCDA – Research Report),
- 05/01/2020
|
Biocardia Announces FDA-Recommended Modifications to Primary Endpoint for Cardiamp Cell Therapy Heart Failure Trial to Support Marketing Approval
- BioCardia®, Inc. [Nasdaq: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today reported that it has accepted and implemented FDA-recommended modifications to the primary endpoint for the CardiAMP® Cell Therapy Heart Failure Trial and associated statistical analysis plan. The primary endpoint going forward will be an outcomes composite score based on a three-tiered Finkelstein-Schoenfeld (FS) hierarchical analysis, an established outcomes design that has been used in other leading heart failure programs. The FS procedure is a ranked analysis that first compares each subject to each other subject for occurrence of first-tier events (time to death, in this case) and then compares patient outcomes for subsequent tiers.
- 04/30/2020
|
82 Biggest Movers From Yesterday
- Gainers
Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) shares climbed 69.4% to close at $19.50 on Tuesday after the company presented positive preclinical and initial clinical data...
- 04/29/2020
|
BioCardia Awarded New U.S. Patent Covering Helix System for Local Biotherapeutic Delivery of Autologous and Allogenic Cells to the Heart
- SAN CARLOS, Calif., April 28, 2020 -- BioCardia®, Inc., (OTC: BCDA), a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today.
- 04/28/2020
|
U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.13%
- U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.13%
- 04/28/2020
|
BioCardia announces litigation financing for Boston Scientific case BCDA;BSX
- BioCardia announces litigation financing for Boston Scientific case BCDA BSX
- 04/14/2020
|
BioCardia Announces Litigation Financing in the Case Captioned Boston Scientific Corp., et al., v. BioCardia Inc.
- BioCardia®, Inc. (BCDA), a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today reported it has entered into an agreement for litigation financing which has been filed today with the Securities and Exchange Commission on Form 8-K. BioCardia, Inc. entered
- 04/14/2020
|
BIOCARDIA REPORTS 2019 FINANCIAL RESULTS AND RECENT BUSINESS HIGHLIGHTS
- SAN CARLOS, Calif., April 09, 2020 -- BioCardia®, Inc. , a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today.
- 04/09/2020
|
BioCardia (OTCMKTS:BCDA) Rating Reiterated by Maxim Group
- Maxim Group reissued their buy rating on shares of BioCardia (OTCMKTS:BCDA) in a research note issued to investors on Wednesday, AnalystRatings.com reports. Maxim Group currently has a $9.00 target price on the stock. Separately, Zacks Investment Research raised shares of BioCardia from a sell rating to a hold rating in a research note on Monday, […]
- 04/05/2020
|
Seasoned Biotech Financial Executive, Jay M. Moyes, Joins Sera Prognostics
- Sera Prognostics, Inc., The Pregnancy Company™, focused on improving maternal and neonatal health through innovative precision biomarker approaches, today announced the appointment of Jay M. Moyes as Chief Financial Officer. Mr. Moyes joins Sera Prognostics as it transitions from rigorous scientific
- 04/02/2020
|
BioCardia (BCDA) Receives a Buy from Maxim Group
- In a report released today, Jason McCarthy from Maxim Group assigned a Buy rating to BioCardia (BCDA), with a price target of $9.00. The company's shares
- 04/01/2020
|
BioCardia (BCDA) Receives a Buy from Maxim Group
- In a report released today,
Jason McCarthy
from Maxim Group assigned a
Buy
rating to BioCardia (
BCDA
–
Research Report
), with a price target of
$9.00
. The company’s shares closed last Wednesday at $3.10.
According to
TipRanks.com
, McCarthy ‘s ran
- 04/01/2020
|
BIOCARDIA ANNOUNCES POSITIVE DSMB RECOMMENDATION TO CONTINUE PHASE III PIVOTAL CARDIAMP HEART FAILURE STUDY, AS PLANNED
- BioCardia (BCDA), a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced that the independent Data Safety Monitoring Board (DSMB) has completed its prespecified data review for the Phase III pivotal CardiAMP™ Heart Failure Trial, based on a review of all available safety data for all patients randomized in the trial. The DSMB indicated there were no safety concerns with the CardiAMP study results and recommended that the trial continue, as planned. The ongoing multi-center, double-blinded, randomized (3:2), controlled pivotal CardiAMP Heart Failure Trial is expected to enroll 260 patients at up to 40 centers nationwide.
- 03/31/2020
|
The Week Ahead In Biotech: Clinical Readouts, COVID-19 News Flow In Focus Amid Continuing Uncertainty
- After starting the week ended March 28 on the backfoot, biotech stocks recovered through the week. Activity in the space remained light, although coronavirus (COVID-19) news flow continued to dominate.Here are the key catalysts that may impact biotech stocks in the unfolding week.Conferences Most conferences
- 03/29/2020
|
Should You Take Comfort From Insider Transactions At BioCardia, Inc. (NASDAQ:BCDA)?
- We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly...
- 03/29/2020
|
The Daily Biotech Pulse: Mylan Ramps Up Manufacturing Of Potential COVID-19 Drug, Lexicon Stops Study Early, Masimo To Buy German Ventilation Company
- Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit 52-week highs March 19.) * Biomerica, Inc. (NASDAQ: BMRA) * Centogene NV (NASDAQ: CNTG) * Gilead Sciences, Inc. (NASDAQ: GILD) * Imara Inc (NASDAQ: IMRA) * Regeneron Pharmaceuticals
- 03/20/2020
|
The Daily Biotech Pulse: Mylan Ramps Up Manufacturing Of Potential COVID-19 Drug, Lexicon Stops Study Early, Masimo To Buy German Ventilation Company
- Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech stocks that hit 52-week highs March 19.)
Biomerica, Inc. (NASDAQ...
- 03/20/2020
|
The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection
- Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 18) * Biomerica, Inc. (NASDAQ: BMRA)( announced commencement of international shipment of rapid COVID-19 test) * BioNTech SE - ADR (NASDAQ: BNTX) *
- 03/19/2020
|
The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection
- Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week highs on March 18)
Biomerica, Inc. (NASDAQ...
- 03/19/2020
|
BIOCARDIA ANNOUNCES TIMING FOR PRESPECIFIED DATA SAFETY MONITORING BOARD REPORT ON PIVOTAL CARDIAMP HEART FAILURE TRIAL
- BioCardia (BCDA), a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced that the independent Data Safety Monitoring Board (DSMB) is expected to report on a prespecified data review for the Phase III pivotal CardiAMP Heart Failure Trial, which will be available for release on Tuesday, March 31, 2020. BioCardia will host a conference call/webcast to provide updates on the CardiAMP Heart Failure Trial featuring national co-principal investigators, Amish Raval, MD, of the University of Wisconsin and Carl Pepine, MD, of the University of Florida, Gainesville, on Tuesday, March 31 at 4:15 p.m. ET. A replay of the webcast will be available for a limited time on the BioCardia website following the presentation.
- 03/12/2020
|
The Daily Biotech Pulse: AstraZeneca Faces Setback In Ovarian Cancer Study, Mallinckrodt To Explore COVID-19 Treatment, Imara IPO
- Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 11) * Bicycle Therapeutics PLC (NASDAQ: BCYC) (reacted to its fourth-quarter results) * Centogene NV (NASDAQ: CNTG) * Tiziana Life Sciences PLC (NASDAQ
- 03/12/2020
|
The Daily Biotech Pulse: AstraZeneca Faces Setback In Ovarian Cancer Study, Mallinckrodt To Explore COVID-19 Treatment, Imara IPO
- Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week highs on March 11)
Bicycle Therapeutics...
- 03/12/2020
|
The Daily Biotech Pulse: Mesoblast To Test Candidate On Coronavirus Symptoms, Proxy Battle Ahead For Rockwell Medical, Glaukos to Join S&P SmallCap 600 Index
- Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit 52-week highs March 9.) * Arcutis Biotherapeutics Inc (NASDAQ: ARQT) * Enzo Biochem, Inc. (NYSE: ENZ) * Centogene NV (NASDAQ: CNTG) * Inovio Pharmaceuticals Inc (NASDAQ:
- 03/10/2020
|
The Daily Biotech Pulse: Mesoblast To Test Candidate On Coronavirus Symptoms, Proxy Battle Ahead For Rockwell Medical, Glaukos to Join S&P SmallCap 600 Index
- Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech stocks that hit 52-week highs March 9.)
Arcutis...
- 03/10/2020
|
Does BioCardia, Inc.'s (NASDAQ:BCDA) CEO Pay Compare Well With Peers?
- In 2002 Peter Altman was appointed CEO of BioCardia, Inc. (NASDAQ:BCDA). First, this article will compare CEO...
- 02/13/2020
|
Contrasting Audentes Therapeutics (NASDAQ:BOLD) and BioCardia (NASDAQ:BCDA)
- Audentes Therapeutics (NASDAQ:BOLD) and BioCardia (OTCMKTS:BCDA) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, earnings, risk, analyst recommendations, profitability and valuation. Analyst Ratings This is a breakdown of current ratings and price targets for Audentes Therapeutics and BioCardia, […]
- 01/28/2020
|
Tech Majors, Boeing, UPS And Tesla On Tap
- Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive th
- 01/25/2020
|
Key events next week - healthcare
- Noteworthy events during the week of January 26 - February 1 for healthcare investors.MONDAY (1/27): European Medicines Agency advisory group CHMP monthly agenda due.TUESDAY (1/28): ASM Biothreats Con
- 01/24/2020
|
Biocardia Announces FDA Clearance for Morph DNA Deflectable Guide Catheter
- SAN CARLOS, Calif., Jan. 14, 2020 -- BioCardia®, Inc. , a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today.
- 01/14/2020
|
BioCardia Announces New U.S. Patent Covering CardiAMP Cell Therapy and Issuance of Two Asian Patents Covering Radial Artery Approach for Cardiac Cell and Gene Therapy Delivery
- BioCardia®, Inc. [NASDAQ: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced the issuance of three new patents for the company’s technologies in the U.S., China and Japan. The new U.S. patent relates to the cell potency assay used in its CardiAMP™ Cell Therapy System, issued as U.S. Patent No: 10,520,505. The patent is for “Methods of Measuring Potential for Therapeutic Potency and Defining Dosages for Autologous Cell Therapies.” The Company also has European patent coverage for this technology.
- 01/08/2020
|
Will BioCardia (NASDAQ:BCDA) Spend Its Cash Wisely?
- Just because a business does not make any money, does not mean that the stock will go down. For example, although...
- 12/30/2019
|
BioCardia Reports 2019 Third Quarter Financial Results and Business Highlights
- SAN CARLOS, Calif., Nov. 19, 2019 -- BioCardia®, Inc. , a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today.
- 11/19/2019
|
Investors Who Bought BioCardia (NASDAQ:BCDA) Shares A Year Ago Are Now Down 80%
- BioCardia, Inc. (NASDAQ:BCDA) shareholders should be happy to see the share price up 21% in the last month. But that...
- 11/11/2019
|
BioCardia to Present at Dawson James Securities 5th Annual Small Cap Growth Conference
- SAN CARLOS, Calif., Oct. 28, 2019 -- BioCardia®, Inc. (Nasdaq: BCDA), a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today.
- 10/28/2019
|
BioCardia Receives CE Mark Renewal For Helix Biotherapeutic Delivery Catheter And Morph Guide Catheter Through May 2024
- SAN CARLOS, Calif., Oct. 08, 2019 -- BioCardia (Nasdaq: BCDA), a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced.
- 10/08/2019
|
BioCardia Announces the Appointment of Two New Board Members
- BioCardia (BCDA), a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced the appointment of experienced CEOs Jim Allen and Andrew Blank to its Board of Directors, effective October 1, 2019. Mr. Allen is Chief Executive Officer and President of Sea Star, Inc., a real estate development company, and has served in that capacity since he founded the company in February 1989. Six of his ventures have resulted in sales to publicly-traded companies.
- 10/02/2019
|
BioCardia Initiates Commercial Release of AVANCE Steerable Introducer Designed to Enhance Physician Control for Complex Cardiac Procedures
- SAN CARLOS, Calif., Oct. 01, 2019 -- BioCardia (Nasdaq: BCDA), a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced.
- 10/01/2019
|
